Sigumir
- Category
- Bioregulators
- Administration routes
- Oral
- Regulatory status
- Not FDA-approved
What it is
A bioregulator peptide complex from cartilage and bone tissue, marketed for joint pain and cartilage health in osteoarthritis. The case is thin: pain relief has only low-confidence support, and mobility claims have limited observational support, while the proposed metabolic effects remain unestablished. The main risk is inconsistent manufacturing quality, with a low chance of allergic reaction to its bovine source. Not an approved drug in the US; it is marketed as a dietary supplement in Russia.
Read Full recordStudied uses & evidence
Studied uses(4)
Reduction of pain in osteoarthritis and osteochondrosis
LowAnimal osteoarthritis models show efficacy; human evidence limited to small uncontrolled observations.
Improved joint mobility and function
SpeculativeSmall reports describe mobility improvements during combined treatment; an isolated Sigumir effect remains unestablished.
Support for cartilage tissue metabolism and trophism
SpeculativeMechanism-based only; supporting studies involve other peptides or bone density, not this peptide.
Evidence limits
- Evidence Level
- Limited Evidence (better than most bioregulators)
Sigumir has two PubMed-indexed clinical studies and a detailed Institute clinical report. The main study tested 33 patients with musculoskeletal conditions against 31 controls over 30-45 day courses. The TMJ study (PMID 22708467) was larger with 62 patients and showed significant improvements. While these represent better evidence than most bioregulators, they still lack double-blind randomization and have not been replicated outside Russia.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(2)
Risks = level of concern: High · Moderate · Low · Theoretical
Allergic reaction to bovine cartilage-derived peptides
LowLack of independent quality control
Moderate
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.